Also in the News…
From FDA approvals and biopharma investor days, to early detection measurements for glaucoma, these are the news stories and studies that caught our attention this week…
Alun Evans | | News
BiblioArchives / LibraryArchives, CC BY 2.0 https://creativecommons.org/licenses/by/2.0, via Wikimedia Commons
FDA approval for new ZEISS excimer laser. ZEISS’ latest excimer laser, the ZEISS MEL 90, has received FDA approval for three major indications (mixed astigmatism, myopia, and hyperopia). Andrew Chang, Head of Global Sales for ZEISS Medical Technology, commented: "With the availability of the ZEISS MEL 90 in the US market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them." Link
Bausch + Lomb EU launch. Bausch + Lomb has announced the launch of its enVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in Europe. Tthe global eye health company states that these monofocal intraocular lenses (IOLs) are designed for broader depth of focus, while astigmatic patients can benefit from enVista Aspire Toric IOLs. Link
Investor Day. Clinical-stage biopharmaceutical company Opthea is to host an in-person/virtual Investor Day on January 28, 2025 at 1:30 PM (ET) in New York City. The event will feature presentations on how to improve vision outcomes in wet AMD patients and provide insights into the commercial potential of the company’s phase III AMD medication, sozinibercept. Link to register
Sleep disruption and AMD links. A Clinical & Experimental Ophthalmology study has investigated the association between nocturnal hypoxia and age-related macular degeneration (AMD). The results reveal that moderate-to-severe obstructive sleep apnea (OSA) is significantly associated with a higher risk of developing neovascular AMD (nAMD), but not early/intermediate AMD or geographic atrophy (GA). The findings suggest that nocturnal hypoxia may be an important modifiable risk factor for severe AMD, warranting further investigation with more comprehensive studies. Link
Early detection of glaucoma. Could macular ganglion cell layer (GCL) thinning offer a more accurate marker for detecting early glaucoma than macular perfusion density (PD) loss? A team of researchers from the Department of Ophthalmology and Visual Sciences at Dalhousie University, Nova Scotia, analyzed OCT and OCTA images and determined that decreases in GCL thickness precede measurable decreases in macular PD. Link
The Ophthalmologist Presents:
Enjoying yourself? There's plenty more where that came from! Our weekly newsletter from The Ophthalmologist brings you the most popular stories as they unfold, chosen by our fantastic Editorial team!
